BR112023004262A2 - Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio - Google Patents

Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio

Info

Publication number
BR112023004262A2
BR112023004262A2 BR112023004262A BR112023004262A BR112023004262A2 BR 112023004262 A2 BR112023004262 A2 BR 112023004262A2 BR 112023004262 A BR112023004262 A BR 112023004262A BR 112023004262 A BR112023004262 A BR 112023004262A BR 112023004262 A2 BR112023004262 A2 BR 112023004262A2
Authority
BR
Brazil
Prior art keywords
binding site
methods
mass spectrometry
hydrogen exchange
exchange mass
Prior art date
Application number
BR112023004262A
Other languages
English (en)
Inventor
Zhang Sisi
Xiao Hui
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112023004262A2 publication Critical patent/BR112023004262A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MÉTODOS PARA IDENTIFICAÇÃO DO SÍTIO DE LIGAÇÃO USANDO ESPECTROMETRIA DE MASSA DE TROCA DE HIDROGÊNIO. A presente invenção refere-se a métodos para identificar um sítio de ligação entre um produto farmacêutico de proteína e uma proteína de célula hospedeira (HCP) usando espectrometria de massa de troca de hidrogênio. O presente pedido também fornece métodos para modificar produtos farmacêuticos de proteína para eliminar a clivagem ou modificação por HCPs. Além disso, o presente pedido fornece métodos para bloquear o sítio de ligação identificado em produtos farmacêuticos de proteína para eliminar a clivagem ou modificação por HCPs.
BR112023004262A 2020-09-11 2021-09-11 Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio BR112023004262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063077220P 2020-09-11 2020-09-11
PCT/US2021/049975 WO2022056336A1 (en) 2020-09-11 2021-09-11 Methods for binding site identification using hydrogen exchange mass spectrometry

Publications (1)

Publication Number Publication Date
BR112023004262A2 true BR112023004262A2 (pt) 2023-04-04

Family

ID=78333247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004262A BR112023004262A2 (pt) 2020-09-11 2021-09-11 Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio

Country Status (11)

Country Link
US (1) US20220082571A1 (pt)
EP (1) EP4211255A1 (pt)
JP (1) JP2023542858A (pt)
KR (1) KR20230066025A (pt)
CN (1) CN116490777A (pt)
AU (1) AU2021342274A1 (pt)
BR (1) BR112023004262A2 (pt)
CA (1) CA3194955A1 (pt)
IL (1) IL301234A (pt)
MX (1) MX2023002924A (pt)
WO (1) WO2022056336A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604345B2 (ja) * 2000-12-21 2011-01-05 住友化学株式会社 タンパク質のｎ末端のアミノ酸配列決定方法
US20020182649A1 (en) * 2001-02-01 2002-12-05 Ciphergen Biosystems, Inc. Methods for protein identification, characterization and sequencing by tandem mass spectrometry
US20050233406A1 (en) * 2002-04-10 2005-10-20 Woods Virgil L Jr Methods for high resolution identification of solvent accessible amide hydrogens in polypeptides and for characterization of polypeptide structure
WO2006020498A2 (en) * 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
US20100212030A1 (en) * 2007-10-19 2010-08-19 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
ES2535963T3 (es) * 2009-02-09 2015-05-19 Roche Glycart Ag Análisis del patrón de glicosilación de inmunoglobulina
ES2567276T3 (es) * 2011-05-12 2016-04-21 Genentech, Inc. Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
WO2015120036A1 (en) * 2014-02-04 2015-08-13 University Of Virginia Patent Foundation Compositions and methods for analysis of protein sequences and post-translational modifications
WO2017097706A1 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Direct affinity measurement of human igg1 binding multimeric antigens
JP6788010B2 (ja) * 2015-12-09 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インビボ相互作用様式を決定するための方法
CN109891244A (zh) * 2016-08-12 2019-06-14 隆扎有限公司 对宿主细胞蛋白质的蛋白质组分析

Also Published As

Publication number Publication date
EP4211255A1 (en) 2023-07-19
MX2023002924A (es) 2023-04-10
KR20230066025A (ko) 2023-05-12
CA3194955A1 (en) 2022-03-17
WO2022056336A1 (en) 2022-03-17
AU2021342274A1 (en) 2023-04-27
CN116490777A (zh) 2023-07-25
US20220082571A1 (en) 2022-03-17
JP2023542858A (ja) 2023-10-12
IL301234A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
BR112022017048A2 (pt) Anticorpos contra sars-cov-2 e métodos para usar os mesmos
BR112022007627A2 (pt) Compostos moduladores do glp-1r
MY202410A (en) Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
CY1119412T1 (el) Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
BR112018002553A8 (pt) Sais de um inibidor de lsd1
BR112016030462A2 (pt) moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
BR112022001460A2 (pt) Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
BR112019007977A2 (pt) composto, composição farmacêutica, método de tratamento ou prevenção de câncer, e, uso de um composto
NO20075635L (no) Antigenbindende molekyler som har modifiserte Fc-regioner og endret binding til Fc-reseptorer
JP2019506866A5 (pt)
WO2018226685A3 (en) METHODS FOR THE SENSITIZATION OF CANCER CELLS TO MEDIATED DESTRUCTION BY T-LYMPHOCYTES BY MOLECULAR PATHWAY MODULATION
ATE433124T1 (de) System und verfahren zum analysieren von radarinformationen
BR112018015590A2 (pt) modulação de receptor acoplado à proteína g (gpcr) por imipridonas
CO6640290A2 (es) Sistema y método para personalizar solicitudes en tiempo real en una interaz de usuario
BR112013025629A2 (pt) padrão quantitativo para espectrometria de massa de proteínas
BRPI0607793A2 (pt) processo para a preparação de moduladores opióides
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
WO2007041820A3 (en) A method for identifying protein patterns in mass spectrometry
BRPI0923582B1 (pt) método, dispositivo, programa e meio de registro de análise da causa de recuperação elástica.
CO2022003582A2 (es) Métodos para el tratamiento de la oftalmopatía tiroidea
BR112023021561A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
BR112021020360A2 (pt) Método, dispositivo de usuário, módulo de veículo e sistema para autenticar uma conexão entre um dispositivo de usuário e um veículo
BR112023001517A2 (pt) Relatório de informações relacionadas à integridade para posicionamento